# Nuclide record locametz (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/locametz/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "locametz" ;
  schema:name "Locametz (kit for Ga-68 gozetotide)"@en ;
  schema:description "Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug."@en ;
  schema:url <https://nuclide.cc/drugs/locametz/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Locametz> ;
  nuclide:status "approved" ;
  nuclide:tag "test" ;
  nuclide:modality "PET imaging agent kit (PSMA, gallium-68)" ;
  schema:alternateName "Locametz" ;
  nuclide:approval "US 2022: PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy", "EU 2022: PSMA PET in prostate cancer" ;
  nuclide:related <https://nuclide.cc/drugs/ga68-psma-11/>, <https://nuclide.cc/drugs/illuccix/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/advanced-accelerator-applications/> ;
  nuclide:terms <https://nuclide.cc/terms/theranostics/> ;
  nuclide:trials <https://nuclide.cc/trials/vision/> .